Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Up 5.7% – Time to Buy?

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX)’s share price rose 5.7% on Friday . The company traded as high as $7.24 and last traded at $7.19. Approximately 13,923 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 350,445 shares. The stock had previously closed at $6.80.

Analysts Set New Price Targets

BDRX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Tuesday, October 14th. Wall Street Zen downgraded shares of Biodexa Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Up 5.7%

The business’s 50 day moving average price is $6.72 and its 200-day moving average price is $9.51.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.